GILEAD SCIENCES, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GILEAD SCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2012 was $435.70M, a 146.57% increase from fiscal 2011.
- GILEAD SCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2011 was $176.71M, a 6.46% decline from fiscal 2010.
- GILEAD SCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2010 was $188.92M, a 0.57% increase from fiscal 2009.
- GILEAD SCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2009 was $187.85M, a 12.92% decline from fiscal 2008.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2012-12-31 | $435.70M 10-K · filed 2013-02-27 | |
| 2011-12-31 | $176.71M 10-K · filed 2013-02-27 | |
| 2010-12-31 | $188.92M 10-K · filed 2013-02-27 | |
| 2009-12-31 | $187.85M 10-K · filed 2012-02-23 | |
| 2008-12-31 | $215.74M 10-K · filed 2011-02-28 | |
| 2007-12-31 | $219.78M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |